<SEC-DOCUMENT>0000950103-22-008354.txt : 20220512
<SEC-HEADER>0000950103-22-008354.hdr.sgml : 20220512
<ACCEPTANCE-DATETIME>20220512123436
ACCESSION NUMBER:		0000950103-22-008354
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220512
FILED AS OF DATE:		20220512
DATE AS OF CHANGE:		20220512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADC Therapeutics SA
		CENTRAL INDEX KEY:			0001771910
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39071
		FILM NUMBER:		22916794

	BUSINESS ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
		BUSINESS PHONE:		41 21 653 02 00

	MAIL ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp172982_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B>&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K<BR>
</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of May 2022.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<HR NOSHADE ALIGN="CENTER" STYLE="width: 21%; color: black">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39071</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADC Therapeutics SA</B></P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Biop&ocirc;le</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Route de la Corniche 3B</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1066 Epalinges</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Switzerland</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 66%; font: 8pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 12pt">Form 20-F</FONT></TD>
    <TD STYLE="width: 14%">
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">&#9746;</P></TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 12pt">Form 40-F</FONT></TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; width: 14%">
</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ADC Therapeutics SA</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: May 12, 2022</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 42%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Michael Forer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Michael Forer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President &amp; General Counsel</FONT></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 85%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Press release dated May 12, 2022</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp172982_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>ADC Therapeutics Announces Abstracts to be Presented
at the European Hematology Association 2022 Hybrid Congress</B></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><I>Oral presentation of pivotal Phase 2 clinical
trial of Cami in relapsed or refractory Hodgkin lymphoma</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><I>ZYNLONTA&reg; diffuse
large B-cell lymphoma data highlighted in several abstracts</I></P>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>LAUSANNE, Switzerland, May 12, 2022</B> &ndash;
ADC Therapeutics SA (NYSE: ADCT), announced today that results from the pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami)
in patients with relapsed or refractory Hodgkin lymphoma have been accepted for an oral presentation at the European Hematology Association
2022 Hybrid Congress (EHA2022), which will be held virtually and in Vienna, Austria from June 9-12, 2022.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&ldquo;We continue to be encouraged by the data
from our ongoing pivotal Phase 2 trial demonstrating the efficacy and safety of Cami as a single agent for patients with relapsed or refractory
Hodgkin lymphoma,&rdquo; said Joseph Camardo, MD, Chief Medical Officer of ADC Therapeutics. &ldquo;As we advance Cami toward a potential
BLA submission, we look forward to sharing these data with the hematology community at EHA2022.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Details of ADC Therapeutics&rsquo; oral presentation are as follows:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E"><B>Camidanlumab Tesirine: Updated Efficacy And Safety
In An Open-Label, Multicenter, Phase 2 Study Of Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (R/R CHL)Presentation Date and Time: Friday, June 10, 2022, 11:45
am &ndash; 12:00 pm CEST // 5:45 am &ndash; 6 am EDT</P>

<P STYLE="margin: 0pt 0; font: 11pt Arial, Helvetica, Sans-Serif; color: #201F1E"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">Presentation Date and Time: Friday, June 10, 2022, 11:45
am &ndash; 12:00 pm CEST // 5:45 am &ndash; 6 am EDT</P>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">Session Title: Hodgkin lymphoma &ndash; Clinical&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">Session Room: Hall A8</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">Abstract Code: S201&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #201F1E">Presenter: Carmelo Carlo-Stella,
MD, Department of Biomedical Sciences, Humanitas University, and Department of Oncology and Hematology, IRCCS Humanitas Research Hospital,
Milan, Italy</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #201F1E">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">Details of ADC Therapeutics&rsquo; poster presentations
are as follows:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E"><B>Health-Related Quality Of Life And Tolerability Of
Loncastuximab Tesirine In High-Risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated In A Phase 2 Clinical Trial
(LOTIS 2)</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">Session Date and Time: Friday, June 10, 2022, 16:30
&ndash; 17:45 CEST // 10:30 am &ndash; 11:45 am EDT</P>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">Location: Hall D</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">Abstract Code: P1717</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E"><B>Real-World Characteristics And Clinical Outcomes
In Relapse/Refractory Diffuse Large B-Cell Lymphoma Patients Who Received Car-T Therapy</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">Session Date and Time: Friday, June 10, 2022, 16:30
&ndash; 17:45 CEST // 10:30 am &ndash; 11:45 am EDT</P>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">Location: Hall D</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">Abstract Code: 1182</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E"><B>Real-World Characteristics And Clinical Outcomes
In Relapse/Refractory Diffuse Large B-Cell Lymphoma Post Car-T Failure</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">Session Date and Time: Friday, June 10, 2022, 16:30
&ndash; 17:45 CEST &ndash; 10:30 am &ndash; 11:45 am EDT</P>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">Location: Hall D</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">Abstract Code: 1181</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">Titles of ADC Therapeutics&rsquo; abstracts accepted
for publication only are as follows:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #201F1E">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; color: #201F1E"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A Phase 2, Open-Label Study Of Loncastuximab Tesirine In Combination With Rituximab (LONCA-R) In Previously Untreated Unfit/Frail
Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9) [Trials in progress]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; color: #201F1E"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma
(DLBCL)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Phase 3 Randomized Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With
R/R DLBCL (LOTIS-5) [Trials in progress]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Please note: times and locations are tentative
and subject to change.</B></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>About Camidanlumab Tesirine (Cami)</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Camidanlumab tesirine (Cami) is an antibody drug conjugate (ADC) comprised
of a monoclonal antibody that binds to CD25 (HuMax<sup>&reg;</sup>-TAC, licensed from Genmab A/S), conjugated to the pyrrolobenzodiazepine (PBD)
dimer payload, tesirine. Once bound to a CD25-expressing cell, Cami is internalized into the cell where enzymes release the PBD-based
payload, killing the cell. This applies to CD25-expressing tumor cells and also to CD25-expressing Tregs. The intra-tumoral release of
its PBD payload may also cause bystander killing of neighboring tumor cells, and PBDs have also been shown to induce immunogenic cell
death. All of these properties of Cami may enhance immune-mediated anti-tumor activity.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Cami is being evaluated in a pivotal Phase 2 clinical trial in patients
with relapsed or refractory Hodgkin lymphoma and a Phase 1b clinical trial as monotherapy and in combination with pembrolizumab in solid
tumors.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>About ZYNLONTA<sup>&reg;</sup> (loncastuximab tesirine-lpyl)</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">ZYNLONTA<sup>&reg;</sup> is a CD19-directed antibody drug conjugate (ADC). Once
bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The
potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results
in cell cycle arrest and tumor cell death.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The U.S. Food and Drug Administration (FDA) has approved ZYNLONTA (loncastuximab
tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of
systemic therapy, including DLBCL not otherwise specified, DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma.
The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease,
including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple
hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved
by the FDA under accelerated approval based on overall response rate and continued approval for this indication may be contingent upon
verification and description of clinical benefit in a confirmatory trial.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">ZYNLONTA is also being evaluated as a therapeutic option in combination
studies in other B-cell malignancies and earlier lines of therapy.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>About ADC Therapeutics</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company
improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Company is advancing its proprietary PBD-based ADC technology to transform
the treatment paradigm for patients with hematologic malignancies and solid tumors.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">ADC Therapeutics&rsquo; CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl)
is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy.
ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2
trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA
and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">ADC Therapeutics is based in Lausanne (Biop&ocirc;le), Switzerland
and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit <FONT STYLE="color: Blue"><U>https://adctherapeutics.com/
</U></FONT>and follow the Company on&nbsp;<FONT STYLE="color: Blue"><U>Twitter</U></FONT>&nbsp;and&nbsp;<FONT STYLE="color: Blue"><U>LinkedIn</U></FONT>.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">ZYNLONTA<SUP><sup>&reg;</sup></SUP>&nbsp;is a registered trademark of ADC Therapeutics
SA.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>CONTACTS:</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Investors</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Eugenia Litz</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">ADC Therapeutics&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="color: Blue"><U>Eugenia.Litz@adctherapeutics.com</U></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">+44 7879 627205</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Amanda Hamilton&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">ADC Therapeutics</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="color: Blue"><U>amanda.hamilton@adctherapeutics.com</U></FONT><U>&nbsp;</U></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">+1 917-288-7023</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>EU Media</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Alexandre M&uuml;ller</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Dynamics Group&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="color: Blue"><U>amu@dynamicsgroup.ch</U></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">+41 (0) 43 268 3231</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>USA Media</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Mary Ann Ondish&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">ADC Therapeutics</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="color: Blue"><U>maryann.ondish@adctherapeutics.com</U></FONT><U>&nbsp;</U></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">+1 914-552-4625</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" != *<# 2(  A$! Q$!_\0
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M2?\ $MM&(CQTD;N_]![?6NC#4'6G;IU,,165*%^I>?XR^(R[%(+%5).!Y;'
M_.F'XR^)<?ZJP_[]'_XJO/:.O%>S]6H_RH\KZQ5_F9[=:_$35IK.&5XK7<Z!
MCA#U(^M3#X@:IG_4VW_?!_QK-TCP5JMSHMC/'Y.R2!&7+]B!5P^!-9 X6$_2
M05GRX/;0\V4LTNVN:Q?@^(EP"//LHF'<HQ7_ !K<L/'&E7;!)2]LY_OC*_F*
MX2Z\,:Q9J6EL9"H_B3YA^F:R2"IP00:'@\/45X_@R5F>.H2M4^YK_ACW2.1)
M8Q)&ZNC<AE.0:=7CVC>(;W19@87+PD_-$Q^4_P"'UKJ/$?Q!MK/1(GTY@U]<
M A4;_ECZD_TK@JX&I":4=4_ZU/:P^;T:M-RG[K73_+N;GB#Q;IGAU,7,ADN"
M,K!'RQ^OH*\TU;XF:U?,RV92RB[",9;\6/\ 3%<A<7$UU.\\\C22N<L['))J
MWI&B:AKEU]GL+=I6ZLW15'J3VKOI8.E25YZONSR:^98C$2Y:>B[+<2XUO5+I
MB9]0NI,_WI6/]:K)>7,;;DN)5;U#$5Z5I_PF3RPVHZBV\]4@7@?B?\*OR?"G
M1V3$=Y>*WJ2I_I0\;AXZ)_@"RS&27,U][U//+'QAKVGL##J<[*/X9&W@_@<U
MW?A_XH07+I;ZS$('/ GC^Y^(ZBL#7/AGJ>FQ//92+>PKR548<#Z=_P *Y&QT
MZ[U*]2SM('DG8X"@=/KZ4W3P]>/,K>NQ,:V,PDU%W]'JG_7D?2$<B2QK)&ZN
MC#*LIR"/:BL/PCH=SH&BK:75V9W)W;?X8_9:*\.:49-1=T?54I2E!2DK/L;U
M%%%2:!117/>,O%$'A30I+Q\-</\ );Q'^-_\!U/_ ->JC%SDHQW9,I**YF<?
M\6/&?V"U/A^PEQ<SK_I+J?N(?X?J?Y?6O$U4NP502Q. !WJ6\O9K^\FN[J4R
M3S.7=V/))KTGX3>#O[0O!K]]%FUMV_T=6'$D@_B^B_S^E>Y&,<+1U_X=GCR<
ML35T_P"&1QWB;PW+X:_LZ&Y)^U7%L)Y4/_+,EB OU  S[U@CK7I?QJ_Y&FR_
MZ\Q_Z&U>:#K6M";G34GU(K14*CBNA]4>%_\ D5-(_P"O.+_T$5K5D^%_^14T
MC_KSB_\ 016M7S]3XWZL]N'PH*PM>\+V>L0LZHL5V!\LBC&3_M>M;M%$*DJ<
MN:+LR*U&G6@X5%='AUU;2V=S);S(5DC;:P-4+VW^T6YP/G7E?\*[_P"(5@L=
MS;WR* 904?W(Z?H?TKB:^CHU?:TU/N?#8J@\/6E3[?ET,K1-)GUS5H+"WX:1
MN6/11W)^@KWW1]'M-$T^.SLXPJ*/F;'+GU/O7$?##2DBDU/4"OS;Q"AQT'WC
M_-:]&KR<?6<I^S6R_,^FRC#1A2]L]Y?D%%%%>>>P%5+73+*RN)[BVMHXI9VW
M2NHY8U;HIIM:(3BFTVM@HHHI#"BBN'\5>+"C/I^G2<CB693^@_QK&O7A0AS3
M.C#8:IB9\D/^&-K6/%=CI;&%#]HN!_ AX7ZFO/M9:/Q'J*WFH0K*R+MC1LE$
M'L/ZUF--'$K33R*B#DNYP*RI_&$8F6WTVU:YE9@JLV0"3TP.IKS*,\=C9/V"
M:7EHOF_Z]#V:U+ 8""]NTWYZOY+^O4ZJ"RMHP EM"H]!&!6M:W$]JJK!*T:K
MT5#@#\JZ'0/#0BTF!M619+YEW2A"0J$_PCGG'K6L=$T\C'V?'T8_XT/+\1?X
MM?5F$LQH/:.GHCS/Q-H,?BJ6.XN[F5+F*/RTD7!&,D\COU->=ZOX1U32 93&
M+FV'_+6$9P/<=17HGC_7V\)^(+:UMK5)K>2W$C!F(8'<PX/X57TKQKI&I,L;
MR&TG/&R?@$^S=*[:5?-L!!3<>>G]^GRU7W-'EUJ>78N;BGR3^[_@/\#T[PM_
MR*>D?]><7_H(K6KD].UN2R1(74/ !A0.P]JZ.UOK>\7,,@)_NG@C\*JACJ6)
MUB[/LQU,+4HJSU7<LT445U&!R/Q! .C6Y/43\?\ ?)KS:N^^(EVOEVEH#\V3
M(1Z=A_6N! S7N86<:6%YZCLE=_(^0S*G/$8_V5%7D[))=STWP  /#\A'4SL3
M_P!\K755P7PVU1)AJ&GD_-$XD4>HZ']0/SKO:\>K*4YN<E:^MO7;\+'U&&A"
MG2C3A+F4=+K:ZT=O*][=UKU"BBBLS<**** "BBB@#G?&&K2Z9I02#(EN"4#C
M^$=_QKR/4=1ATZ RS'+'[B#JQKT7XFW,=GI5K/*<(C-^)P.*\"O;V6_NFGF/
M)X5>RCT%<M++98[%MU/X<;?/K9?JST99G#+\$E37[R=_ETN_T0Z_U&XU&7?.
MWRC[J#[JUZA\(_!WFRCQ'?1_NT)6T1AU;N_X=![Y]*XCP5X6F\5:_':#*VL?
MSW$@_A3T^IZ#_P"M7TM;6T-G:Q6UO&L<,2A$11PH'05[^*J0H4U0I*WIT7_!
M/G:$9UZCKU7=^?5DM%%%>4>B>&?&K_D:;+_KS'_H;5YI7I?QJ_Y&FR_Z\Q_Z
M&U>:9QS7T&%_@Q]#Q,3_ !9'TUHFE6U]X3TDNNV3['%\Z_[HZU5NM"OK5M]N
M3(!T*=1^%9F@^.[&T\/Z=;M:SEH[:-201SA0/6K[?$.QQ\MG.3[L!7S^(R9U
M9N7)9WW1ZE#/:%&*C[1.W1W_ ,AB>(=2LFV2CS,?PR+S_C5@>-T0?O;(Y_V7
M_P#K5C:AX]EN4*0V$"CL91O-<I-=S3RM([\L<G P/R%%/)L:EI52]=15.)<M
MOK2<O33\_P#(MZQ?RZIJ4MW,>7/"CHH["LJYG6W@9^_0>YJY9V5SJ-RL%O&T
MDC'@"NHUOX=-)X?1K1R^HPY=ES\LGJH]QV]:[HX-4YQ>-J\]ME:T5YVZ_,\R
M68.O"HLMH*FG?FE>\W?=*3VOU2Z=3S_P[K<V@ZW#?QY8*<2+_?4]17OVGZA;
M:I8Q7EI*)(9!D$=O8^AKYNDC>&1HY$9'4X96&"#6MH7B74O#TY>RF_=L?GB?
ME&^H_K7?B\+[9<T=SSLOS!X9N$U>+_ ^A**\\L?BO82(HOK&:)^YB(8?KBKL
MOQ1T%$S''=R-_=$8']:\IX2NG;E/?68X5J_.CMJS(/$.E7.K3:9%>1F[BX*9
MZGT![D=Q7F&O?$R_U&)[?3XOL4+#!<-F0CZ]OP_.N'61UE$BNP<'(8'G-==+
M+I.+=1V9P8C.8QDE15UU_P" ?35%<?\ #_5=:U32V?4T#0)Q#.W#R?X@>O\
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MG;VK*%>*7,WMOOY_KV-JF&FWRJ/Q+3;R?Y=R\LEW=Q73)=>289Y%&V,-E1C
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@"A5>2^[!R3QTQZ45M0GSPNMOZ[F.)@X5.5Z/^NVA_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
